CJC-1295 won't be found on pharmacy shelves in Carrè or most other cities — this is a specialist compound supplied via a dedicated online market. This matters because CJC-1295 quality ranges widely across the market — from verified research-grade material to mislabeled or underdosed compounds — and the vendor determines everything about the product. What consistently distinguishes top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety screening. The sections below cover what Carrè researchers need to know about purchasing, testing, and working with CJC-1295 for legitimate research applications.
What Studies Say About CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Carrè researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
The first step for any Carrè researcher sourcing CJC-1295 is identifying 2-3 vendors with documented positive community reputations — search results alone are too heavily influenced by marketing spend. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are within acceptable research limits. The combination of peer feedback and direct document verification is the gold standard for CJC-1295 sourcing — community feedback surfaces patterns individual COA review misses, and vice versa. The dry lyophilised powder of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Carrè
COA-verified · International tracking · Research grade
CJC-1295 operates beyond the scope of approved drug regulation — researchers should understand that the known safety profile is based on academic studies rather than pharmaceutical approval data. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. Endotoxin testing in the CJC-1295 COA is absolutely required — gram-negative bacterial endotoxins can trigger severe inflammatory responses at trace quantities, and no pricing advantage justifies skipping this verification. For any individual considering CJC-1295 outside a formal research context: speak with a healthcare professional — this compound is unapproved for human therapeutic application and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
